The Southern California Stem Cell Seminar Series for February ,

“Using Patient iPSCs to Generate Safe and Effective Drugs for Heart Disease and Cancer”

Seminar Speaker Mark Mercola, Ph.D.; Department of Cardiovascular Medicine; Stanford Medical School

Hosted by Host: Evan Snyder, MD, PhD; Professor of Human Genetics Program, Director, Center for Stem Cells & Regenerative Medicine, Sanford Children’s Health Research Center Lab Website

Mark Mercola Bio

Dr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.

Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.

Prof. Mercola received an NIH MERIT award for his work on heart formation, and authored over 130 papers. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the NIH, California Institute for Regenerative Medicine and the Fondation Leducq.

Sign up to receive notifications regarding events for Stem Cell and Regenerative Medicine Inter-institutional community Ucsdscpevents-L